|
Jul 21
|
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
|
|
Jul 18
|
Orion Group Half-Year Financial Report January–June 2025
|
|
Jul 18
|
Orion Corporation’s financial reporting and Annual General Meeting in 2026
|
|
Jul 11
|
Looking for a Growth Stock? 3 Reasons Why Orion OYJ (ORINY) is a Solid Choice
|
|
Jul 11
|
Recent Price Trend in Orion OYJ (ORINY) is Your Friend, Here's Why
|
|
Jul 9
|
Inside information: Orion upgrades full-year outlook for 2025
|
|
Jul 9
|
3 Stocks In The Global Market That May Be Undervalued July 2025
|
|
Jun 17
|
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs
|
|
Jan 2
|
3 Leading Dividend Stocks Yielding Up To 8.5%
|
|
Dec 30
|
Orion and Marinus terminate agreement for ganaxolone in Europe
|
|
Oct 14
|
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
|
|
Aug 8
|
Orion Group Half-Year Financial Report January–June 2024
|
|
Aug 8
|
Orion Corporation’s financial reporting and Annual General Meeting in 2025
|
|
Jul 25
|
Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
|
|
Feb 13
|
Notice to the Annual General Meeting of Orion Corporation
|
|
Feb 13
|
Orion Group Financial Statement Release January–December 2023
|
|
Jan 11
|
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting
|
|
Jan 11
|
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion’s result in 2023
|
|
Jan 8
|
Orion Corporation: Managers’ transactions – Ari Lehtoranta
|
|
Jan 8
|
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
|